Literature DB >> 22840591

Cytokine profiles in various graft-versus-host disease target organs following hematopoietic stem cell transplantation.

Hsiu-Yu Lai1, Teh-Ying Chou, Cheng-Hwai Tzeng, Oscar Kuang-Sheng Lee.   

Abstract

Previous studies using genetic-deficient murine models suggest that different T-helper subsets may contribute to different types of tissue damages in graft-versus-host disease (GvHD). However, there is limited information available on the distribution of T-helper cytokines in the various GvHD target tissues. In the current study, an acute GvHD murine model was set up to directly assess the in situ cytokine profiles in various GvHD tissue lesions; in addition, we also studied GvHD tissues from patients who had undergone bone marrow transplantation procedures. We observed that interferon-γ (IFN-γ was dominant in murine liver and gastrointestinal tissue lesions, whereas IFN-γ and interleukin 17 (IL-17) were abundant in murine skin lesions. Furthermore, in human GvHD tissues, interleukin 4 (IL-4) and IFN-γ were predominant in liver lesions and colon lesions, respectively, while no specific cytokine was prevalent in human GvHD skin lesions. In addition, a low ratio of CD4(+) T helper (Th) versus CD8(+) T cytotoxic (Tc) cells in human GvHD tissue lesions, especially in the liver, was detected, and this contrasts with the situation in murine GvHD tissues where CD4(+) Th cells were predominant. Dual staining for CD markers and cytokine expression showed that IFN-γ-secreting T cells were enriched in all murine GvHD target tissue lesions, and Tc1 and Tc2 cells were predominant in human GvHD colon and liver sections, respectively. However, IFN-γ(+) Th1, IL-17(+) Th17, IFN-γ(+) Tc1, and IL-17(+) Tc17 cells were slightly more frequent in human skin lesions compared to IL-4(+) Th2 and IL-4(+) Tc2 cells. To sum up, these results suggest that differences in cytokine imbalances may significantly contribute to tissue-specific pathogenesis in GvHD target organs, and CD8(+) Tc cells may play an important role in human GvHD induction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22840591     DOI: 10.3727/096368912X653110

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  11 in total

1.  Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD.

Authors:  N Alam; W Xu; E G Atenafu; J Uhm; M Seftel; V Gupta; J Kuruvilla; J H Lipton; H A Messner; D D H Kim
Journal:  Bone Marrow Transplant       Date:  2015-03-16       Impact factor: 5.483

2.  Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.

Authors:  Jaitip Tipanee; Ermira Samara-Kuko; Thierry Gevaert; Marinee K Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2022-06-16       Impact factor: 12.910

3.  Local immune cell infiltration in cutaneous acute graft versus host disease.

Authors:  Rachel Sennett; Burhan M Jama; Brian Hinds; Dimitrios Tzachanis; Gerald P Morris; Amanda F Marsch
Journal:  Int J Womens Dermatol       Date:  2020-05-22

4.  Kinetics of IFN-γ and IL-17 Production by CD4 and CD8 T Cells during Acute Graft-versus-Host Disease.

Authors:  Ji-Min Ju; Hakmo Lee; Keunhee Oh; Dong-Sup Lee; Eun Young Choi
Journal:  Immune Netw       Date:  2014-04-21       Impact factor: 6.303

5.  Role of CD8 Regulatory T Cells versus Tc1 and Tc17 Cells in the Development of Human Graft-versus-Host Disease.

Authors:  Adriana Gutiérrez-Hoya; Rubén López-Santiago; Jorge Vela-Ojeda; Laura Montiel-Cervantes; Octavio Rodríguez-Cortés; Víctor Rosales-García; Vladimir Paredes-Cervantes; Raúl Flores-Mejía; Daniela Sandoval-Borrego; Martha Moreno-Lafont
Journal:  J Immunol Res       Date:  2017-01-09       Impact factor: 4.818

6.  Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease.

Authors:  Sina Naserian; Mathieu Leclerc; Allan Thiolat; Caroline Pilon; Cindy Le Bret; Yazid Belkacemi; Sébastien Maury; Frédéric Charlotte; José L Cohen
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

7.  Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies.

Authors:  Shouheng Lin; Lin Cheng; Wei Ye; Shanglin Li; Diwei Zheng; Le Qin; Qiting Wu; Youguo Long; Simiao Lin; Suna Wang; Guohua Huang; Peng Li; Yao Yao; Xiaofang Sun
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

8.  DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo.

Authors:  Masaki Ohyagi; Tetsuya Nagata; Kensuke Ihara; Kie Yoshida-Tanaka; Rieko Nishi; Haruka Miyata; Aya Abe; Yo Mabuchi; Chihiro Akazawa; Takanori Yokota
Journal:  Nat Commun       Date:  2021-12-22       Impact factor: 14.919

Review 9.  Determining the Quantitative Principles of T Cell Response to Antigenic Disparity in Stem Cell Transplantation.

Authors:  Ali Salman; Vishal Koparde; Charles E Hall; Max Jameson-Lee; Catherine Roberts; Myrna Serrano; Badar AbdulRazzaq; Jeremy Meier; Caleb Kennedy; Masoud H Manjili; Stephen R Spellman; Dayanjan Wijesinghe; Shahrukh Hashmi; Greg Buck; Rehan Qayyum; Michael Neale; Jason Reed; Amir A Toor
Journal:  Front Immunol       Date:  2018-10-11       Impact factor: 7.561

10.  A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy.

Authors:  Shengchao Xu; Xi Yan; Gan Dai; Chengke Luo
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.